Article info
PDFTreatments
Original research
Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease
- Correspondence to Dr Hiroshi Kida; kida.hiroshi.sv{at}mail.hosp.go.jp; Dr Kiyoharu Fukushima; fukushima{at}imed3.med.osaka-u.ac.jp
Citation
Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease
Publication history
- Received August 13, 2022
- Accepted December 29, 2022
- First published January 23, 2023.
Online issue publication
February 14, 2024
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.